Patel Naimish's Form 4 filing
CRISPR Therapeutics AG (CRSP) · filed Jun 1, 2026
- Accession no.
- 0001193125-26-251817
- Filed
- Jun 1, 2026
- Trade date
- May 28-29, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $210.6K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Patel NaimishCIK 0002021679 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 28, 2026 | Common Shares | MOption exerciseAcquired | +10,000 | – | – | 23,143 | Direct | |
| May 29, 2026 | Common Shares | SSaleDisposed | −3,786 | $55.62 | −$210,577.32 | 19,357 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 28, 2026 | Common Shares | MOption exerciseDisposed | −10,000 | – | – | 20,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.